PubRank

R T D Oliver

Author PubWeight™ 13.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Post-biopsy rise in serum PSA. A potential tool for the dynamic evaluation of prostate cancer/prostatic intraepithelial neoplasia (PIN). Cancer Biol Ther 2003 1.37
2 Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 2005 1.07
3 Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome. Histopathology 2007 0.89
4 Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004 0.86
5 Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer Prostatic Dis 2000 0.86
6 Influence of circumcision and sexual behaviour on PSA levels in patients attending a sexually transmitted disease (STD) clinic. Prostate Cancer Prostatic Dis 2001 0.85
7 Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol 2005 0.84
8 IPM chemotherapy in cytokine refractory renal cell cancer. Br J Cancer 2003 0.84
9 DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer 2002 0.81
10 GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer 2007 0.79
11 p53 and MDM2 in germ cell cancer treatment response. J Clin Oncol 2002 0.78
12 Detection of genetic alterations in primary bladder carcinoma with dual-color and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2004 0.77
13 Molecular characterisation of the t(1;15)(p22;q22) translocation in the prostate cancer cell line LNCaP. Cytogenet Genome Res 2006 0.76
14 Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2002 0.76
15 Cure of testicular germ cell cancer: an index of access to healthcare. Natl Med J India 2002 0.75
16 Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer 2003 0.75
17 Sexual factors and prostate cancer. BJU Int 2004 0.75
18 FSH in testis cancer. Re: Nord C, Bjøro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E, Fosså SD. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003;44:322-8. Eur Urol 2004 0.75
19 The frequency of intratubular embryonal carcinoma: implications for the pathogenesis of germ cell tumours. Histopathology 2004 0.75
20 Comparative study of peptides isolated from class I antigen groove of urological specimens. a further step toward the future of peptide therapy in bladder cancer patients. Urol Int 2002 0.75
21 Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. Surg Oncol 2009 0.75
22 Comparative study between direct mild acid extraction and immunobead purification technique for isolation of HLA class I-associated peptides. Urol Int 2002 0.75
23 Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporos Int 2008 0.75
24 Isolation of human leukocyte antigen (HLA)-associated peptide(s) in the absence of HLA-restricted specific cytolytic T lymphocytes. Urol Int 2002 0.75